PHARMACYCLICS, INC.

Inactive Instrument

Pharmacyclics, Inc. Share Price

Equities

US7169331060

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2015	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
2015	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE

Latest news about Pharmacyclics, Inc.

Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	07/15/07	RE
Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	29/15/29	RE
Mylan NV : Generic drugmaker Teva makes $40 billion offer for rival Mylan	22/15/22	RE
Mylan NV : Exclusive - Perrigo expected to reject Mylan offer as soon as this week	22/15/22	RE
Actavis : Generic drugmaker Mylan offers $29 billion for Perrigo	09/15/09	RE
AbbVie : CEO defends Pharmacyclics deal to sceptical investors	06/15/06	RE
Wall Street closes up slightly ahead of jobs report	06/15/06	RE
AbbVie : CEO says new form of Humira could thwart generics	05/15/05	RE
AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	05/15/05	RE
AbbVie : Biotech buys get pharma M&A off to flying start in 2015	05/15/05	RE
AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	05/15/05	RE
Dai ichi Life Insurance : U.S. futures flat with Dow, S&P at record levels	02/14/02	RE

Press releases Pharmacyclics, Inc.

Pharmacyclics : Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma	08/16/08	PU
Pharmacyclics : AbbVie’s Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers	08/16/08	PU
Pharmacyclics : IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent	08/16/08	PU
Pharmacyclics : AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment–Naïve Chronic Lymphocytic Leukemia	08/16/08	PU
Pharmacyclics : IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenström’s Macroglobulinemia in Europe	08/16/08	PU

More press releases

News in other languages on Pharmacyclics, Inc.

Wall Street se reprend un peu dans un climat d'attente	06/15/06
DJ Industrial : Wall Street se reprend un peu dans un climat d'attente	06/15/06
AbbVie : Début d'année en fanfare pour les fusions dans la pharmacie	05/15/05
AbbVie : Wall Street quasiment stable après les chiffres du chômage	05/15/05
Apple : Les valeurs à suivre sur les marchés américains	05/15/05

Managers and Directors - Pharmacyclics, Inc.

Managers	Title	Age	Since
Wulff-Erik von Borcke CEO	Chief Executive Officer	-	01/15/01
Betty Chang CTO	Chief Tech/Sci/R&D Officer	-	09/13/09
Heow Tan CTO	Chief Tech/Sci/R&D Officer	65	01/12/01

Company Profile

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.77%	42.75B
LONZA GROUP AG	+47.70%	41.61B
MODERNA, INC.	+12.24%	41.34B
CELLTRION, INC.	-8.83%	26.59B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.12B
MEDPACE HOLDINGS, INC.	+30.56%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.76B
UNITED THERAPEUTICS CORPORATION	+8.35%	11B

Other Biotechnology & Medical Research

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer